Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paolo Gaibani

Showing results (1-10 of 154) with videos related to

Pageof 16
Sort By:
Microbes and Infection|June 13, 2017
An overview of Usutu virusPaolo Gaibani, Giada Rossini
Heliyon|March 11, 2025
Prophages in <i>Bacteroides fragilis</i>: Distribution and genetic diversityPaolo Gaibani, Rocco Latorre
International Journal of Antimicrobial Agents|June 12, 2025
In vitro activity of Cefepime/Enmetazobactam against Klebsiella pneumoniae carrying bla<sub>KPC</sub> allelic variants conferring resistance to Ceftazidime/AvibactamLuca Caiazzo, Edoardo Carretto, Paolo Gaibani
Antimicrobial Agents and Chemotherapy|May 28, 2026
Case Commentary: When susceptibility is not enough in recurrent <i>Burkholderia cenocepacia</i> infectionSimone Giuliano, Paolo Gaibani, Carlo Tascini
The Journal of Antibiotics|February 5, 2026
Synergy evaluation of cefepime/enmetazobactam in combination with novel β-lactam/β-lactamase inhibitor combinations (βL/βLICs) against Klebsiella pneumoniae carrying different bla<sub>KPC</sub> variantsCarlo Tascini, Giulia Zocche, Paolo Gaibani
Methods in Molecular Biology (Clifton, N.J.)|May 29, 2016
Diagnostic Methods for CHIKV Based on Serological ToolsPaolo Gaibani, Maria Poala Landini, Vittorio Sambri
Antibiotics (Basel, Switzerland)|January 28, 2026
Epidemiology of ESBL-Producing, Carbapenem-Resistant, and Carbapenemase-Producing Enterobacterales in Southern AfricaPearl Ntshonga, Giacomo Maria Paganotti, Paolo Gaibani
Journal of Global Antimicrobial Resistance|July 1, 2022
Genome characterization of a Klebsiella pneumoniae co-producing OXA-181 and KPC-121 resistant to ceftazidime/avibactam, meropenem/vaborbactam, imipenem/relebactam and cefiderocol isolated from a critically ill patientPaolo Gaibani, Stefano Amadesi, Tiziana Lazzarotto, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|February 6, 2022
In vitro activity of imipenem-relebactam against KPC-producing Klebsiella pneumoniae resistant to ceftazidime-avibactam and/or meropenem-vaborbactamDonatella Lombardo, Simone Ambretti, Tiziana Lazzarotto, et al.
The Journal of Antimicrobial Chemotherapy|April 12, 2026
Synergistic activity of cefepime/enmetazobactam with meropenem, piperacillin, piperacillin/tazobactam, cefiderocol and fosfomycin against Klebsiella pneumoniae carrying blaKPC allelic variantsAlice Crema, Ajwa Shafique, Gabriele Bianco, et al.
Pageof 16

Showing results (1-10 of 154) with videos related to

Sort By:
Pageof 16
Microbes and Infection|June 13, 2017
An overview of Usutu virusPaolo Gaibani, Giada Rossini
Heliyon|March 11, 2025
Prophages in <i>Bacteroides fragilis</i>: Distribution and genetic diversityPaolo Gaibani, Rocco Latorre
International Journal of Antimicrobial Agents|June 12, 2025
In vitro activity of Cefepime/Enmetazobactam against Klebsiella pneumoniae carrying bla<sub>KPC</sub> allelic variants conferring resistance to Ceftazidime/AvibactamLuca Caiazzo, Edoardo Carretto, Paolo Gaibani
Antimicrobial Agents and Chemotherapy|May 28, 2026
Case Commentary: When susceptibility is not enough in recurrent <i>Burkholderia cenocepacia</i> infectionSimone Giuliano, Paolo Gaibani, Carlo Tascini
The Journal of Antibiotics|February 5, 2026
Synergy evaluation of cefepime/enmetazobactam in combination with novel β-lactam/β-lactamase inhibitor combinations (βL/βLICs) against Klebsiella pneumoniae carrying different bla<sub>KPC</sub> variantsCarlo Tascini, Giulia Zocche, Paolo Gaibani
Methods in Molecular Biology (Clifton, N.J.)|May 29, 2016
Diagnostic Methods for CHIKV Based on Serological ToolsPaolo Gaibani, Maria Poala Landini, Vittorio Sambri
Antibiotics (Basel, Switzerland)|January 28, 2026
Epidemiology of ESBL-Producing, Carbapenem-Resistant, and Carbapenemase-Producing Enterobacterales in Southern AfricaPearl Ntshonga, Giacomo Maria Paganotti, Paolo Gaibani
Journal of Global Antimicrobial Resistance|July 1, 2022
Genome characterization of a Klebsiella pneumoniae co-producing OXA-181 and KPC-121 resistant to ceftazidime/avibactam, meropenem/vaborbactam, imipenem/relebactam and cefiderocol isolated from a critically ill patientPaolo Gaibani, Stefano Amadesi, Tiziana Lazzarotto, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|February 6, 2022
In vitro activity of imipenem-relebactam against KPC-producing Klebsiella pneumoniae resistant to ceftazidime-avibactam and/or meropenem-vaborbactamDonatella Lombardo, Simone Ambretti, Tiziana Lazzarotto, et al.
The Journal of Antimicrobial Chemotherapy|April 12, 2026
Synergistic activity of cefepime/enmetazobactam with meropenem, piperacillin, piperacillin/tazobactam, cefiderocol and fosfomycin against Klebsiella pneumoniae carrying blaKPC allelic variantsAlice Crema, Ajwa Shafique, Gabriele Bianco, et al.
Pageof 16